COVID-19 in people living with human immunodeficiency virus : a case series of 33 patients
INTRODUCTION: Data on people living with human immunodeficiency virus (PLWH) in the current SARS-CoV-2 pandemic are still scarce. This case series of 33 PLWH patients with COVID-19 reveals symptoms and outcome in this special population.
METHODS: Retrospective analysis of anonymized data including age, gender, HIV-associated parameters, symptoms, and outcome.
RESULTS: Three out of 32 patients with documented outcomes died (9%). 91% of the patients recovered and 76% have been classified as mild cases. All patients were on antiretroviral treatment, of them 22 on tenofovir-containing regimen and 4 on the protease inhibitor darunavir.
CONCLUSIONS: This preliminary case series does not support excess morbidity and mortality among symptomatic COVID-19 PLWH and with viral suppression on ART. SARS-CoV-2 infections may occur during boosted darunavir-based and/or on tenofovir-containing ART.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:48 |
|---|---|
| Enthalten in: |
Infection - 48(2020), 5 vom: 11. Okt., Seite 681-686 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Härter, Georg [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
99YXE507IL |
|---|
| Anmerkungen: |
Date Completed 07.10.2020 Date Revised 16.02.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s15010-020-01438-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM309774810 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM309774810 | ||
| 003 | DE-627 | ||
| 005 | 20231225134644.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s15010-020-01438-z |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1032.xml |
| 035 | |a (DE-627)NLM309774810 | ||
| 035 | |a (NLM)32394344 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Härter, Georg |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19 in people living with human immunodeficiency virus |b a case series of 33 patients |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.10.2020 | ||
| 500 | |a Date Revised 16.02.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: Data on people living with human immunodeficiency virus (PLWH) in the current SARS-CoV-2 pandemic are still scarce. This case series of 33 PLWH patients with COVID-19 reveals symptoms and outcome in this special population | ||
| 520 | |a METHODS: Retrospective analysis of anonymized data including age, gender, HIV-associated parameters, symptoms, and outcome | ||
| 520 | |a RESULTS: Three out of 32 patients with documented outcomes died (9%). 91% of the patients recovered and 76% have been classified as mild cases. All patients were on antiretroviral treatment, of them 22 on tenofovir-containing regimen and 4 on the protease inhibitor darunavir | ||
| 520 | |a CONCLUSIONS: This preliminary case series does not support excess morbidity and mortality among symptomatic COVID-19 PLWH and with viral suppression on ART. SARS-CoV-2 infections may occur during boosted darunavir-based and/or on tenofovir-containing ART | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a AIDS | |
| 650 | 4 | |a Antiretroviral therapy | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a HIV infection | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 7 | |a Tenofovir |2 NLM | |
| 650 | 7 | |a 99YXE507IL |2 NLM | |
| 650 | 7 | |a Darunavir |2 NLM | |
| 650 | 7 | |a YO603Y8113 |2 NLM | |
| 700 | 1 | |a Spinner, Christoph D |e verfasserin |4 aut | |
| 700 | 1 | |a Roider, Julia |e verfasserin |4 aut | |
| 700 | 1 | |a Bickel, Markus |e verfasserin |4 aut | |
| 700 | 1 | |a Krznaric, Ivanka |e verfasserin |4 aut | |
| 700 | 1 | |a Grunwald, Stephan |e verfasserin |4 aut | |
| 700 | 1 | |a Schabaz, Farhad |e verfasserin |4 aut | |
| 700 | 1 | |a Gillor, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Postel, Nils |e verfasserin |4 aut | |
| 700 | 1 | |a Mueller, Matthias C |e verfasserin |4 aut | |
| 700 | 1 | |a Müller, Markus |e verfasserin |4 aut | |
| 700 | 1 | |a Römer, Katja |e verfasserin |4 aut | |
| 700 | 1 | |a Schewe, Knud |e verfasserin |4 aut | |
| 700 | 1 | |a Hoffmann, Christian |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Infection |d 1973 |g 48(2020), 5 vom: 11. Okt., Seite 681-686 |w (DE-627)NLM00001740X |x 1439-0973 |7 nnns |
| 773 | 1 | 8 | |g volume:48 |g year:2020 |g number:5 |g day:11 |g month:10 |g pages:681-686 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s15010-020-01438-z |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 48 |j 2020 |e 5 |b 11 |c 10 |h 681-686 | ||